Introduction: Whenever feasible, sleeve lobectomy is recommended to avoid pneumonectomy for lung cancer, but these guidelines are based on limited retrospective series. The aim of our study was to compare outcomes following sleeve lobectomy and pneumonectomy using data from a national database.
Perspective
Sleeve lobectomy leads to higher rates of overall and disease-free survival despite an increased risk of postoperative pulmonary complications. When it is technically possible, sleeve lobectomy has to be the type of resection to favor for central tumor.
See Editorial Commentary page 196.
Complete surgical resection is the cornerstone of the management of localized non-small cell lung cancer (NSCLC). For years, surgical resection was restricted to segmentectomy, lobectomy, and pneumonectomy (PN), the last being associated with the highest postoperative morbidity and mortality. 1 Sleeve lobectomy (SL) was first described for carcinoma by Allison in 1959, 2 to avoid the burden of PN in frail patients with compromised lung function. Given the morbidity and mortality associated with PN, SL was initially restricted to patients with compromised lung function who would not tolerate PN. However, the indication for SL has progressively expanded to any tumor that may be completely resected using this technique, particularly on the right side. 3 As a result of this progressive expansion of SL over PN, recent guidelines from the American College of Chest Physicians recommend SL rather than PN in patients with clinical stage I or II central NSCLC in whom complete resection can be achieved. 4 However, these guidelines are based on short surgical series comparing recent SL to historical PN, or meta-analyses that included patients operated on over many decades. 5 No database analysis has been published to date, although every lung cancer surgeon is now able to perform SL and PN, and recent publications have highlighted the influence of surgery improvements on the prognosis of NSCLC during recent decades. 6 We therefore sought to compare short and long-term outcomes following SL and PN for NSCLC during the past decade in France. For this, we used the French national database Epithor and 2 PS methods: matching and the inverse probability of treatment weighting (IPTW), combined with a sensitivity analysis.
MATERIALS AND METHODS Data Collection
Epithor (EPId emiologie en chirurgie THORacique) is a governmentrecognized clinical database that is financially supported by the French National Cancer Institute for data-quality monitoring. Epithor is accredited by French Health Authorities, a governmental agency dedicated to improving the quality of patient care and to guaranteeing equality within the health care system, as a methodologically appropriate tool to assess professional surgical practices. Participating in Epithor is now a requirement for medical accreditation and thoracic surgery unit certification in France. 7, 8 The accuracy of data collection is checked via regular external onsite audits initiated in 2010. 7 Data are sent by Internet to the national database; surgeons and patients are anonymous. Surgeons can check the quality of the way they enter the data by comparing their data with national data through a quality score ranging from 0% to 100%. Moreover, participants have to check the quality of the local database for missing values by comparing its completeness with that of the national database. This comparison is expressed through a quality score ranging from 0% to 100%. A score exceeding 80% is mandatory to have the local data incorporated in the national database and to benefit from the accreditation. Every surgeon receives a personal quality score, thus inciting them to update their data. This induces a virtuous cycle. Almost all of the teams that participate in Epithor have a score above 80% for data entry.
The Institutional Review Board of the French Society of Thoracic and Cardiovascular Surgery approved the electronic prospective database used for this study and the study itself. Patients' consent was obtained, and patients were aware that the data collected would be used for clinical research purposes.
The institutional review board of the French Society of Thoracic and Cardiovascular Surgery certifies that this study respects the current regulations that govern clinical research in France, referenced as CERC-SFCTCV-2015-8-14-16-5-39-PAPi.
Study Population
From January 2005 to December 2014, 6259 patients underwent SL or PN for NSCLC in 103 centers in France. The baseline demographic and clinical characteristics included age, sex, American Society of Anesthesiologists score, World Health Organization (WHO) performance status, body mass index (BMI), forced expiratory volume in 1 second (FEV1) as a percentage, and dyspnea score according to the Medical Research Council. 9 The number of comorbid diseases per patient was considered a categorical variable because recent data from Epithor consistently suggested that this variable was superior to individual comorbidities in a predictive model for operative mortality. 10 Systematic nodal dissection included node sampling or radical lymphadenectomy. NSCLC histology was classified according to the most recent WHO classification. 11 Tumor and nodal stages were classified postoperatively according to the pathologic examination and the most recent International Association for the Study of Lung Cancer classification. 12 
Outcome Measurements
The primary end point was postoperative complications, which included cardiopulmonary morbidity, bronchopleural fistula (BPF), empyema, and hemorrhage. Cardiopulmonary morbidity was reported as proposed by the European Society of Thoracic Surgery and included postoperative pulmonary complications (eg, pneumonia, atelectasis requiring bronchoscopy, acute respiratory distress syndrome [ARDS], mechanical ventilation for more than 2 days, and arrhythmia). 13 The secondary end points were postoperative mortality, defined as any patient who died within the first 30 days following surgery, or the initial hospitalization if longer; length of hospital stay, overall survival (OS), defined as the time from surgery until death from any cause or the last follow-up visit; and disease-free survival (DFS), defined as the time from surgery until disease recurrence or the last follow-up visit.
Variables Used for Propensity Score Analysis
Variables used to estimate the propensity score (PS) were age, sex, performance status, number of comorbidities, dyspnea score, FEV1, BMI, induction chemotherapy, side, histology, T status, N status, year of surgery, type of center, and hospital volume.
Missing Data
The proportion of missing FEV1 values for this study was 7%. We assumed that the missing data were missing at random. We applied a multiple imputation framework (20 imputations 
Statistical Analysis
The PS is the conditional probability of assignment to a particular treatment given a vector of observed covariates.
14 PS techniques were used to balance the distributions of measured potentially confounding covariates for patients treated by SL or PN. A mirrored histogram was used to measure the discriminatory ability of PS matching, and the standardized difference for the IPTW analysis. Matching and IPTW tend to eliminate systematic differences between experimental and control subjects to a greater degree than does stratification or covariate adjustment. 15, 16 Matching used a search algorithm to find a set of weights for each covariate such that the version of optimal balance is achieved after matching. 17 We used 1:1 matching without replacement in descending order with a caliper of 0.01. With IPTW, each individual is weighted by the inverse probability of receiving the treatment that they actually received. In this way, each group is weighted to represent the full population sample, thus revealing treatment effects. We evaluated 2 PS techniques for their ability to balance the measured covariates between SL and PN by reducing the standardized difference. 16 The standardized difference is the difference between sample means in the SL and PN group divided by the standard deviation in the treatment group overall. 18 Finally, odds ratios (ORs) were used for dichotomous variables such as postoperative mortality, atelectasis, pneumonia, arrhythmia, BPF, empyema and hemorrhage, ventilation > 2 days, and ARDS. Logistic models were used. For the length of hospital stay, the difference of means was used. Logistic models and linear regression were used. For OS and DFS, we used the adjusted Kaplan-Meier estimators for curves using IPTW data and the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs). Hospital-level clustering was used to estimate the robust standard error for each coefficient of the logistic model, linear regression, and Cox model.
Sensitivity Analysis
The Mantel-Haenszel Q test statistic was used; if Ѓ ¼ 1, the statistic test is significant and the study is free of hidden bias. 19 If the value of the Q test is greater, then the study is insensitive to bias. 20 
RESULTS

Study Cohort
From 2005 to 2014, 941 SLs and 5318 PNs were included in the Epithor database and make up the study cohort. Compared with the PN group, patients in the SL group were characterized by younger age (median age, 62 years for both groups), higher BMI (median, 25 for both groups), higher FEV1, lower American Society of Anesthesiologists score, lower WHO status, and less frequent induction therapy (Table 1) . Compared with the PN group, the SL group was characterized by the predominance of right-sided surgery and squamous cell carcinoma. T and N stages in the SL group were lower than those in the PN group (Table 1) .
Surgery (Video 1)
More than half of the SLs involved the right upper lobe, followed by the left upper, left lower, and right lower, respectively. Middle lobectomy and bilobectomy SL occurred in <5% of patients each (Table 1) . Both SL and PN were predominantly performed in teaching hospitals.
SL was more frequently performed in high-volume centers, whereas PN was more frequently performed in low-volume centers. The number of SLs increased during the past decade, whereas the number of PNs decreased steadily (Table 1) .
PS Estimation
The mirrored histogram shows the good distribution of the covariates after PS matching ( Figure 1) .
The median distribution of standardized biases was 0.024 for the matching approach (first and third quartile, 0.013 and 0.0355), and 0.04 for IPTW (first and third quartile, 0.0145 and 0.0654). The standardized difference never reached the value of 10%, which highlighted that the 2 groups were well balanced for covariates by matching and IPTW. 21 See Table 2 .
Postoperative Mortality
Postoperative mortality was 4.99% (n ¼ 47) in the SL group and 5.89% (n ¼ 313) in the PN group (P ¼ .279). There were no significant differences in postoperative mortality between SL and PN, according to the 2 PS methods, with an OR associated with PN of 1.24 (95% confidence interval [CI], 0.74-2.1) for matching, and 0.77 (95% CI, 0.4-1.5) for IPTW (OR ¼ 1 for SL) ( Table 3) .
Postoperative Complications and Length of Hospital Stay
Postoperative pulmonary complications overall (eg, pneumonia, atelectasis requiring bronchoscopy, ARDS, and mechanical ventilation for more than 2 days) were significantly less frequent in the PN group than in the SL group according to the 2 PS methods (Table 3 ). In detail, only atelectasis and pneumonia were significantly less frequent following PN whatever the PS analysis performed. The 2 PS methods showed a trend toward a higher rate of postoperative arrhythmia, and a significantly higher rate of BPF and empyema in the PN group than in the SL group (Table 3 ). The incidence of hemorrhage was significantly higher in the PN group but only by matching (Table 3) . BPF occurred in 2.6% of patients in the PN group (n ¼ 138) and 1.59% in SL group (n ¼ 15) (P ¼ .067). In the PN group, there was no significant difference in the occurrence of BPF whether the patient receive preoperative irradiation (3.17%, n ¼ 4) or not (2.34%, n ¼ 122) (P ¼ .679). Length of hospital stay was significantly shorter in the SL group than in the PN group by matching but not by IPTW analysis (Table 3) .
OS and DFS
The median follow-up time was 10.89 months (first and third quartile, 1.66 and 15) for OS and 9.6 months (first and third quartile, 1 and 14) for DFS. From the 941 patients of the SL group, 463 were evaluable at 1 month, 174 at Thoracic: Lung Cancer Pag es et al Figure 2) .
Three-year DFS was 46.41% AE 4.01% for the SL group and 31.63% AE 1.59% for the PN group. Compared with SL, there was an increased risk of recurrence in the PN group by matching, with HR of 1.49 (95% CI, 1.1-2), but not by the IPTW method (Table 3 and Figure 3 ).
Sensitivity Analysis
For the matching analysis, the Mantel-Haenszel Q statistic test was used and showed a potential hidden bias (Q value close to 1) only for postoperative mortality (Table  E1) . For postoperative complications, the Q value was high, indicating the study was insensitive to a bias. 19 These results confirmed that compared with SL, PN was associated with a significant decrease in the rate of pulmonary complications overall (eg, pneumonia, atelectasis requiring bronchoscopy, ARDS, and mechanical ventilation for more than 2 days); a significant decrease in the rate of atelectasis and pneumonia considered separately; a nonsignificant increase in the rate of arrhythmias; and a significant increase in the risk of BPF, empyema, and hemorrhage. For the IPTW method, the sensitivity analysis confirmed these data, except for arrhythmias and hemorrhages (Table E2) .
DISCUSSION
Reminder of the Main Results
In studying outcomes after PN and SL for NSCLC using data from a nationwide database, 2 PS methods concluded that SL was not associated with any significant difference in postoperative mortality, but with a significant increase in the rate of pulmonary complications (eg, atelectasis or pneumonia), and a significant decrease in the rate of BPF and empyema compared with PN. Matching analysis also found that SL was associated with improved 3-year OS compared with PN, but not IPTW analysis.
Treatment Allocation
Initially developed for patients with insufficient pulmonary reserve, which did not allow PN, SL has now become widely accepted as a reliable and safe procedure to allow the complete resection of NSCLC. 22 Indeed, SL makes it possible to spare lung parenchyma, and thus provides better postoperative FEV1 than that achieved with PN. [23] [24] [25] Quality of life after SL is also better than that after PN, as highlighted by Balduyck and colleagues, 26 who reported a high burden of dyspnea, general pain, thoracic pain, and shoulder dysfunction after PN. This is the first time that the influence of SL on postoperative complications, mortality, and long-term survival had been reported in the context of a large study based on a national database, which allows the analysis of real-life events. In this respect, one can assume that over the past decade all French thoracic surgeons were able to perform both procedures. The choice to perform 1 procedure rather than the other was therefore based on disease severity and the patient's clinical status rather than technical preferences. This probable difference between groups in baseline characteristics of patients and tumors constitutes the strongest argument in favor of adequate statistical analysis, including PS analysis, of this large real-life dataset.
Postoperative Mortality and Postoperative Complications
We found no significant difference regarding postoperative mortality between SL and PN groups, whatever the statistical method used. In a recent article from the Epithor Group, Morgant and colleagues 6 reported PN and bronchial SL to be major prognostic factors associated with postoperative death following lung cancer surgery, with ORs ranging from 4.4 to 8.2 for PN and 2.4 to 2.9 for bronchial SL. In a recent meta-analysis that included more than 3800 patients, Shi and colleagues 5 showed a significant difference in postoperative mortality favoring SL over PN with an OR of 0.5 (95% CI, 0.34-0.72). Similarly, in a matching analysis comparing SL and PN, Park and colleagues 27 found postoperative mortality to be significantly lower in the SL group (1%) than in the PN group (8.6%; P < .0001). In contrast, we found no difference between SL and PN for postoperative mortality, despite a significantly greater incidence of BPF and empyema after PN. We found no influence of preoperative irradiation on the occurrence of BPF after PN, as already highlighted in a recent article establishing a predictive score for BPF. 28 This absence of difference can be attributed either to the low mortality associated with PN, or to the high mortality associated with SL in our study.
On one hand, recent publications tend to disfavor PN, which, for example, was associated with a mortality rate of 7.8% over the past decade in the French database. 28 On the other hand, in our study, mortality following SL remained far higher than that reported in the most recent studies, 5, 22, 24 and markedly higher than the 2.7% reported after regular lobectomy in the same database. 7 Indeed, in our study, postoperative atelectasis and pneumonia were significantly more frequent after SL than after PN, whatever the statistical method considered. This high rate of parenchymal complications may explain the increased postoperative mortality after SL than after regular lobectomy. 7 Altogether, these data suggest that the improvement in patient selection and postoperative care developed in PN should be applied to SL to decrease its postoperative morbidity and mortality. 
OS and DFS
We found that OS was lower in the PN group than in the SL group only by matching. Similar results were reported in the meta-analysis by Shi and colleagues, 5 with a combined HR of 0.63 (95% CI, 0.56-0.71), and in the matching analysis by Park and colleagues 27 (5-year OS for PN vs SL, 32.1% vs 58.4%, respectively; P ¼ .0002). In our study, patients undergoing PN were significantly more likely to have T3 and T4 tumors and N2 lymph-node involvement than were patients undergoing SL. The TNM classification alone might lack precision: T stages have recently been separated according to tumor size, 29 the N stage might need to be deciphered according to the number of lymphatic chains and stations involved, 30 and the number of molecular biomarkers is constantly increasing. 31 However, as in our study, the meta-analysis by Shi and colleagues 5 showed significantly more advanced disease in the PN group (47.96% of stage III in the PN group vs 38.32% in the SL group; P<.001), which could explain by itself the worse prognosis in patients who underwent PN.
Therefore, PS methods tend to balance the distributions of potentially confounding covariates, but the lack of precision of the covariates measured might limit the influence of PS in this setting. Compared with the SL group, the PN group had significantly more recurrences according to matching. These findings were different from those of Park and colleagues, 27 whose sample size was too small to draw any definitive conclusions, or by Shi and colleagues, 5 whose matching analysis allowed a more powerful comparison of OS and DFS following SL and PN.
However, the 2 PS analyses did not provide the same results, and the lower OS and DFS in the PN group were not significant in the IPTW analysis. It is important to bear in mind that, unlike randomized assignments of treatments, PS typically does not balance covariates that were not observed. 32 Matching reduces the sample size because matches may not be found for some patients, whereas weighting allows the comparison of expectations and distributions between treated and untreated subjects. 16, 33 The combination of matching and IPTW tends to eliminate systematic differences between experimental and control subjects to a greater degree than does stratification or covariate adjustment. 15, 16 Even if these 2 techniques well balanced the distribution of the covariates, they do not permit us to conclude which provides the true results and also raise the question of the reality of the results published in studies using only matching analysis. Given the differences in the results of matching and IPTW, the Values are presented as n (%), except for overall propensity score. *A standardized difference>0.1 (10%) represents meaningful imbalance in a given variable between treatment groups. yNumber of procedures per year. results for long-term survival and recurrence should be interpreted with caution.
Strengths and Limitations
To the best of our knowledge, this is the first study to compare SL and PN using a large dataset, a national database, 2 PS methods, and a sensitivity analysis. The main strengths of this study are the use of a national database, which provided a large number of patients, and a homogeneous population. The large number of patients in both groups allowed powerful comparisons. The homogeneous population reduced the sample size needed for the matching comparison and the reasonable length of study period tended to decrease historical bias.
However, any study involving a large database raises the question of the quality and exhaustiveness of the prospectively entered data, such as comorbidities, and observational studies are notoriously full of no responses and missing values. 28 Few details were available about the surgical technique, especially concerning bronchial stump coverage and pulmonary artery reconstruction. We used PS to create comparable cohorts; however, we cannot be certain that the PS perfectly neutralized all of the confounding variables, as suggested by the differences in the results for the 2 methods used.
The main limitation of this study is the dramatic loss of follow-up data (50% of missing data after only 1 month of follow-up), which could be explained by various factors: at the visit 1 month after surgery, some patients are not seen by a thoracic surgeon but by a medical oncologist or pneumologist; and some surgeons do not always enter follow-up data into the Epithor database; for example, when they hear news about the patients or correspondence announcing their death.
Moreover, we must underline that PS cannot replace randomized control trials. In randomized controlled trials, random allocation of patients to either an experimental or a control arm guarantees that treatment allocation is unrelated to measured and unmeasured patients' characteristics. It enables researchers to draw unbiased conclusions about a treatment effect, provided that the number of randomized patients is large enough to minimize random variation. 34 Although this study has a high level of evidence, the conclusions that can be drawn will never be as strong as those from prospective multicenter randomized controlled trials, which seem to be impossible to conduct nowadays.
CONCLUSIONS
Despite the limits of our study, especially the dramatic loss of follow-up data, we highlight SL, which could lead to better 3-year OS and DFS compared with PN for patients with NSCLC.
Whenever it is technically possible, surgeons must perform SL to provide more long-term survival benefits to patients even with the risk of more postoperative pulmonary complications.
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